NASDAQ:APTX

Aptinyx Competitors

$2.63
-0.09 (-3.31 %)
(As of 04/20/2021 04:40 PM ET)
Add
Compare
Today's Range
$2.57
Now: $2.63
$2.70
50-Day Range
$2.68
MA: $3.10
$3.72
52-Week Range
$2.42
Now: $2.63
$6.47
Volume277,293 shs
Average Volume538,209 shs
Market Capitalization$176.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47

Competitors

Aptinyx (NASDAQ:APTX) Vs. XENE, LXRX, KPTI, ZIOP, CALT, and ICPT

Should you be buying APTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Aptinyx, including Xenon Pharmaceuticals (XENE), Lexicon Pharmaceuticals (LXRX), Karyopharm Therapeutics (KPTI), ZIOPHARM Oncology (ZIOP), Calliditas Therapeutics AB (publ) (CALT), and Intercept Pharmaceuticals (ICPT).

Xenon Pharmaceuticals (NASDAQ:XENE) and Aptinyx (NASDAQ:APTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares Xenon Pharmaceuticals and Aptinyx's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xenon Pharmaceuticals$6.83 million97.26$-41,600,000.00($1.54)-12.05
Aptinyx$3.67 million47.99$-57,410,000.00($1.71)-1.54

Xenon Pharmaceuticals has higher revenue and earnings than Aptinyx. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Aptinyx, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Xenon Pharmaceuticals and Aptinyx, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xenon Pharmaceuticals00503.00
Aptinyx10802.78

Xenon Pharmaceuticals presently has a consensus price target of $25.25, indicating a potential upside of 36.12%. Aptinyx has a consensus price target of $11.6667, indicating a potential upside of 343.60%. Given Aptinyx's higher possible upside, analysts plainly believe Aptinyx is more favorable than Xenon Pharmaceuticals.

Profitability

This table compares Xenon Pharmaceuticals and Aptinyx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xenon Pharmaceuticals-102.25%-21.76%-16.08%
Aptinyx-2,108.05%-46.43%-44.60%

Institutional and Insider Ownership

79.9% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.9% of Aptinyx shares are owned by institutional investors. 8.4% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of Aptinyx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Xenon Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Aptinyx has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Summary

Xenon Pharmaceuticals beats Aptinyx on 9 of the 14 factors compared between the two stocks.

Aptinyx (NASDAQ:APTX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Profitability

This table compares Aptinyx and Lexicon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptinyx-2,108.05%-46.43%-44.60%
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Aptinyx and Lexicon Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptinyx10802.78
Lexicon Pharmaceuticals06202.25

Aptinyx currently has a consensus price target of $11.6667, indicating a potential upside of 343.60%. Lexicon Pharmaceuticals has a consensus price target of $9.40, indicating a potential upside of 92.62%. Given Aptinyx's stronger consensus rating and higher possible upside, analysts clearly believe Aptinyx is more favorable than Lexicon Pharmaceuticals.

Institutional and Insider Ownership

43.9% of Aptinyx shares are owned by institutional investors. Comparatively, 84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. 8.6% of Aptinyx shares are owned by company insiders. Comparatively, 6.4% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Aptinyx and Lexicon Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptinyx$3.67 million47.99$-57,410,000.00($1.71)-1.54
Lexicon Pharmaceuticals$322.07 million2.19$130.13 million$1.353.61

Lexicon Pharmaceuticals has higher revenue and earnings than Aptinyx. Aptinyx is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Aptinyx has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500.

Karyopharm Therapeutics (NASDAQ:KPTI) and Aptinyx (NASDAQ:APTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Valuation & Earnings

This table compares Karyopharm Therapeutics and Aptinyx's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karyopharm Therapeutics$40.89 million17.33$-199,590,000.00($3.22)-2.93
Aptinyx$3.67 million47.99$-57,410,000.00($1.71)-1.54

Aptinyx has lower revenue, but higher earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Aptinyx, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Karyopharm Therapeutics and Aptinyx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Karyopharm Therapeutics-221.23%-187.66%-56.42%
Aptinyx-2,108.05%-46.43%-44.60%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Karyopharm Therapeutics and Aptinyx, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Karyopharm Therapeutics01802.89
Aptinyx10802.78

Karyopharm Therapeutics currently has a consensus target price of $29.8750, indicating a potential upside of 216.47%. Aptinyx has a consensus target price of $11.6667, indicating a potential upside of 343.60%. Given Aptinyx's higher possible upside, analysts plainly believe Aptinyx is more favorable than Karyopharm Therapeutics.

Institutional & Insider Ownership

88.6% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 43.9% of Aptinyx shares are held by institutional investors. 13.3% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 8.6% of Aptinyx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Karyopharm Therapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Aptinyx has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Summary

Aptinyx beats Karyopharm Therapeutics on 8 of the 13 factors compared between the two stocks.

ZIOPHARM Oncology (NASDAQ:ZIOP) and Aptinyx (NASDAQ:APTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Volatility and Risk

ZIOPHARM Oncology has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Aptinyx has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Profitability

This table compares ZIOPHARM Oncology and Aptinyx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ZIOPHARM OncologyN/A-48.49%-43.53%
Aptinyx-2,108.05%-46.43%-44.60%

Analyst Ratings

This is a breakdown of current ratings and price targets for ZIOPHARM Oncology and Aptinyx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ZIOPHARM Oncology03202.40
Aptinyx10802.78

ZIOPHARM Oncology presently has a consensus target price of $5.90, suggesting a potential upside of 86.12%. Aptinyx has a consensus target price of $11.6667, suggesting a potential upside of 343.60%. Given Aptinyx's stronger consensus rating and higher possible upside, analysts plainly believe Aptinyx is more favorable than ZIOPHARM Oncology.

Earnings and Valuation

This table compares ZIOPHARM Oncology and Aptinyx's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZIOPHARM Oncology$150,000.004,548.00$-117,800,000.00($0.34)-9.32
Aptinyx$3.67 million47.99$-57,410,000.00($1.71)-1.54

Aptinyx has higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than Aptinyx, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

48.0% of ZIOPHARM Oncology shares are held by institutional investors. Comparatively, 43.9% of Aptinyx shares are held by institutional investors. 2.3% of ZIOPHARM Oncology shares are held by insiders. Comparatively, 8.6% of Aptinyx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Aptinyx beats ZIOPHARM Oncology on 8 of the 14 factors compared between the two stocks.

Aptinyx (NASDAQ:APTX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Profitability

This table compares Aptinyx and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptinyx-2,108.05%-46.43%-44.60%
Calliditas Therapeutics AB (publ)N/A-26.80%-25.38%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Aptinyx and Calliditas Therapeutics AB (publ), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptinyx10802.78
Calliditas Therapeutics AB (publ)00503.00

Aptinyx presently has a consensus price target of $11.6667, suggesting a potential upside of 343.60%. Calliditas Therapeutics AB (publ) has a consensus price target of $40.80, suggesting a potential upside of 56.80%. Given Aptinyx's higher possible upside, equities research analysts clearly believe Aptinyx is more favorable than Calliditas Therapeutics AB (publ).

Valuation & Earnings

This table compares Aptinyx and Calliditas Therapeutics AB (publ)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptinyx$3.67 million47.99$-57,410,000.00($1.71)-1.54
Calliditas Therapeutics AB (publ)$19.56 million33.22$-3,450,000.00($0.19)-136.95

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Aptinyx. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Aptinyx, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

43.9% of Aptinyx shares are held by institutional investors. Comparatively, 11.9% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 8.6% of Aptinyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Calliditas Therapeutics AB (publ) beats Aptinyx on 7 of the 13 factors compared between the two stocks.

Aptinyx (NASDAQ:APTX) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Risk and Volatility

Aptinyx has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500.

Profitability

This table compares Aptinyx and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptinyx-2,108.05%-46.43%-44.60%
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Aptinyx and Intercept Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptinyx10802.78
Intercept Pharmaceuticals115802.29

Aptinyx presently has a consensus price target of $11.6667, suggesting a potential upside of 343.60%. Intercept Pharmaceuticals has a consensus price target of $50.6957, suggesting a potential upside of 144.08%. Given Aptinyx's stronger consensus rating and higher possible upside, equities research analysts clearly believe Aptinyx is more favorable than Intercept Pharmaceuticals.

Valuation & Earnings

This table compares Aptinyx and Intercept Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptinyx$3.67 million47.99$-57,410,000.00($1.71)-1.54
Intercept Pharmaceuticals$252 million2.74$-344,680,000.00($10.89)-1.91

Aptinyx has higher earnings, but lower revenue than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Aptinyx, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

43.9% of Aptinyx shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 8.6% of Aptinyx shares are held by company insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Aptinyx beats Intercept Pharmaceuticals on 8 of the 13 factors compared between the two stocks.


Aptinyx Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$18.55-6.8%$709.73 million$6.83 million-19.12
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.88-0.8%$698.67 million$322.07 million-4.65Upcoming Earnings
Decrease in Short Interest
News Coverage
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.44-2.2%$692.81 million$40.89 million-3.26News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17-0.9%$675.74 million$150,000.00-4.53News Coverage
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.02-3.4%$671.97 million$19.56 million-18.72
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.80-2.9%$666.59 million$252 million-2.13
Chimerix logo
CMRX
Chimerix
1.3$7.91-1.8%$665.73 million$12.52 million-13.88
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.61-1.1%$662.95 million$2.22 million-15.35News Coverage
Gap Down
Veru logo
VERU
Veru
1.4$8.88-2.4%$653.68 million$42.59 million-31.71Analyst Report
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.67-4.6%$650.06 million$17.26 million-4.08
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.32-4.2%$648.83 million$13.80 million-14.16Analyst Report
News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.83-3.1%$637.44 million$5.09 million-6.38
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.20-2.1%$632.17 millionN/A-2.30Increase in Short Interest
News Coverage
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$31.51-4.4%$628.85 million$9.64 million-5.13
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.84-6.5%$616.02 millionN/A-4.35Analyst Upgrade
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.67-1.9%$604.18 million$143.01 million-1.08
OrganiGram logo
OGI
OrganiGram
1.6$2.34-11.1%$603.91 million$64.61 million-3.44Analyst Downgrade
Decrease in Short Interest
Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.91-0.7%$595.21 million$8 million-8.08
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.56-1.0%$592.94 millionN/A-9.87Analyst Report
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.55-2.3%$591.17 million$59.29 million-23.67Increase in Short Interest
News Coverage
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.67-0.5%$577.60 millionN/A-16.05
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$23.61-2.1%$573.91 million$12.69 million-11.35Increase in Short Interest
News Coverage
Gap Up
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$42.87-0.6%$563.31 million$195.89 million122.49
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.57-5.2%$551.05 million$26.74 million18.93News Coverage
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$17.86-0.6%$547.04 millionN/A-5.19
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.55-2.3%$534.08 million$1.19 million-6.90
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.84-1.0%$521.18 millionN/A-4.63News Coverage
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.4$11.02-1.1%$518.23 millionN/A-8.54
Inventiva logo
IVA
Inventiva
0.0$13.27-0.9%$517.26 millionN/A0.00
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$13.85-1.2%$513.60 millionN/A-3.99
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.04-0.2%$510.88 million$25 million-18.52
Provention Bio logo
PRVB
Provention Bio
1.6$7.81-3.1%$510.17 millionN/A-5.24Analyst Report
Increase in Short Interest
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.61-1.0%$509.84 millionN/A-5.44
89bio logo
ETNB
89bio
1.6$25.81-1.9%$505.03 millionN/A-5.11Insider Selling
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.64-3.0%$498.07 millionN/A-8.13
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.18-3.5%$495.20 million$59.22 million40.90
XBiotech logo
XBIT
XBiotech
1.0$16.48-1.7%$493.73 millionN/A1.14News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.50-1.9%$493.31 million$58.12 million-15.70Gap Up
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.96-4.5%$492.36 million$57.49 million-6.69News Coverage
Akouos logo
AKUS
Akouos
1.6$14.60-2.4%$490.23 millionN/A0.00
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$33.20-7.7%$483.22 million$40,000.00-1.44Upcoming Earnings
AC Immune logo
ACIU
AC Immune
1.3$6.51-0.0%$468.31 million$111.75 million-7.23Analyst Upgrade
Analyst Revision
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.96-4.1%$464.67 million$22.27 million-3.90Analyst Revision
News Coverage
Evolus logo
EOLS
Evolus
1.5$10.55-0.7%$464.44 million$34.92 million-5.20
Verastem logo
VSTM
Verastem
1.3$2.71-0.4%$463.50 million$17.46 million-1.92
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.17-0.9%$456.10 million$49.65 million-1.65
Verona Pharma logo
VRNA
Verona Pharma
1.7$7.58-2.1%$448.42 millionN/A-2.30
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.81-1.7%$448.40 millionN/A-11.86News Coverage
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.39-1.8%$447.49 million$102.31 million6.55Increase in Short Interest
News Coverage
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.